可选产品分析
经您允许，我们会使用注重隐私的有限分析来了解哪些研究流程有效。我们不会使用广告跟踪器或会话录制。您可以在偏好设置中更改此选择。请阅读 隐私政策.
Accelerated worldwide adoption of the inVue Dx cellular analyzer platform (surpassing 9,000 placements) and Cancer Dx liquid biopsy screening, which could expand diagnostic test utilization per pet visit beyond current house assumptions.
U.S.
IDEXX Laboratories Inc. (NASDAQ: IDXX) is rated Sell as the equity trades well above fundamental business value. While the company's proprietary razor-blade diagnostic model commands strong pricing power and high customer retention, prevailing market valuations discount unsustainable compounding that leaves investors exposed to severe multiple contraction.
IDEXX Laboratories represents one of healthcare's premier mature compounders, distinguished by a classic razor-blade model where an 11% YoY expansion in its global premium instrument installed base generates an enduring, high-margin stream of recurring consumable and reference lab revenues. In Q2 2026, the company posted 10% reported revenue growth to $1,216.59 million and delivered a 35.0% operating margin. Supported by the placement of over 9,000 inVue Dx cellular analyzers, customer retention remains in the high 90s globally. Management raised FY2026 guidance to revenue of $4,700M-$4,745M and of $14.69-$14.94, reflecting 70 to 90 basis points of operating margin expansion.
However, market valuation has completely detached from underlying cash flow reality. At 31.45x forward earnings, the market prices in cash flow growth exceeding 19% annually, whereas fundamental projections model sustainable revenue growth of 7.0% to 9.8%. Unadjusted sell-side consensus 12-month targets averaging $698.00 (discounted to $631.36 present-value equivalent at a 10.555% cost of equity,) rely on unanchored forward multiples >40x that fail to reflect fundamental capital costs.24
Furthermore, operational headwinds are emerging at the clinical practice level. U.S. same-store clinical visits declined 1.3% in Q2 2026, with wellness visits down over 3%, signaling discretionary pet care spending constraints. Simultaneously, FY2026 capital expenditures are stepping up to ~$180 million, increasing the reinvestment rate to 12%. Given stretched multiples relative to peers like Agilent (26.07x P/E), any operational deceleration will trigger severe multiple compression. We conclude that capital must be liquidated under a Sell rating.35
IDEXX commands an expanding global premium instrument installed base that grew 11% year-over-year. Once proprietary analyzers (Catalyst, ProCyte, inVue Dx) are embedded in a veterinary practice, high switching costs, staff retraining requirements, and workflow disruption secure high-90s% customer retention rates globally.5
The company's practice management software and VetConnect cloud ecosystem integrate point-of-care instruments seamlessly with commercial reference laboratories, creating substantial operational workflow lock-in across clinics in over 175 countries.
IDEXX operates an unmatched worldwide reference laboratory logistics network offering rapid turnaround, enabling competitive market-share captures; 20% of initial Cancer Dx testing volume stems from practices previously utilizing competing laboratories.5
Sell. IDEXX is a premier compounder saddled with an untenable valuation. Trading at a 64.96% premium to its $342.77 fair value midpoint, the stock offers an implied return of -39.38% and exposes investors to severe multiple compression.
IDEXX Laboratories, Inc. is a global leader in veterinary pet healthcare diagnostics and software services. Headquartered in Westbrook, Maine, the company operates across more than 175 countries, providing diagnostic products and software solutions to veterinary practices, livestock producers, and water testing facilities. The business operates through three reportable segments: Companion Animal Group (CAG), Water, and Livestock, Poultry and Dairy (LPD).
The economic core of the company is the Companion Animal Group, which generated $3,953.29 million, or 91.86% of consolidated revenues in FY2025. CAG provides in-clinic point-of-care laboratory analyzers (Catalyst, ProCyte, inVue Dx), proprietary consumable test cartridges, rapid assay tests, reference laboratory diagnostic services, and digital practice management systems (VetConnect Plus). The Water testing segment generated $201.15 million and LPD generated $131.79 million in FY2025.
A macroeconomic downturn compounded by persistent veterinary clinic visit contractions—where clinical wellness visits decline more than 5.0% YoY following the 1.3% visit decline in Q2 2026 —would severely curtail consumable cartridge replenishment and reference lab submissions. Under this scenario, top-line growth decelerates to 6.5%, operating margins compress to 31.0% under wage inflation, and the forward valuation multiple contracts toward 22.0x-23.0x P/E. Because the shares trade at $565.45, representing a 64.96% premium over the house fair value midpoint of $342.77, equity holders face severe asymmetric downside in any operational downshift.
Prolonged veterinary clinic visit contraction and discretionary spending trade-down restrict consumable testing volume, capping revenue growth at 6.5%-7.5% and causing operating margin expansion to stall at 31.0%. Under multiple compression toward specialized diagnostics peers (Agilent at 26.07x), intrinsic equity value declines toward the fair value lower bound of $283.61.
IDEXX trades at 31.45x forward P/E, well above diagnostics peers such as Agilent at 26.07x. A de-rating toward 23.0x forward earnings as organic revenue growth moderates into mid-single digits would reduce intrinsic valuation by 21.4%.34
可能削弱我们投资逻辑的五项变化。
Depresses recurring consumable cartridge run-rates, increases customer churn, and erodes instrument placement economics.
当前：-1.3% total clinical visits, wellness visits down below 3% in Q2 2026
触发警报：Wellness visits contracting more than 5.0% YoY
IDEXX Laboratories possesses a wide competitive moat rooted in its proprietary in-clinic diagnostic instrument platform, integrated practice management software, and expansive worldwide reference laboratory infrastructure. The company operates a classic razor-blade business model where placement of proprietary point-of-care analyzers (such as Catalyst, ProCyte, and the newly launched inVue Dx) establishes an enduring annuity of high-margin recurring consumables. In Q2 2026, CAG Diagnostics recurring revenue reached $974.71 million, representing 87.2% of total CAG revenue, driven by 13.6% organic growth in VetLab consumables. High switching costs arise because veterinary technicians and clinicians are trained extensively on IDEXX hardware and software interfaces, creating customer retention rates in the high 90s globally.
The moat is further widened by IDEXX's proprietary VetConnect cloud software ecosystem, which connects in-clinic point-of-care results with commercial reference laboratories and practice information systems. This integrated workflow makes it administratively burdensome and clinically inefficient for a practice to defect to competing hardware or reference labs. Scale advantages also present a formidable barrier to entry: IDEXX's dedicated veterinary salesforce, specialized logistical courier networks, and extensive diagnostic test menu cannot be easily replicated by general human diagnostic companies or smaller specialized competitors. Even in a competitive market, 20% of new Cancer Dx testing volume originates from accounts converting from rival laboratories.
These structural advantages are sustained through continuous proprietary menu expansion and long-term customer lock-in. With over 9,000 inVue Dx analyzers installed and growing international placements, veterinary clinics remain economically and procedurally tied to the IDEXX diagnostic infrastructure for the lifespan of their capital assets.
IDEXX generates extraordinary economic profit, delivering FY2025 operating income of $1,360.03 million on revenue of $4,303.70 million, representing an operating margin of 31.60% against the health care industry benchmark of 15.50%. With a firm weighted average cost of capital of 10.41%, the company achieves an economic profit spread in excess of 15 percentage points on invested capital.26
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
The highlighted cell is Fair value when every assumption sits at its base level ($342.77). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $1.1B after modeled reinvestment of $146.8M, with terminal value at 73.5% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
The modal path reflects steady execution of IDEXX's core strategy. Revenue expands at a 5-year CAGR of 8.25%, moving from $4,725.46 million in FY2026 to $6,398.72 million in FY2030. Operating margins widen from 31.60% in FY2025 to 32.40% in FY2026 and normalize at 34.00% by FY2030. Diluted shares decrease at 0.6%-1.2% annually, driving EPS from $14.84 in FY2026 to $22.59 in FY2030. Terminal multiple normalizes to 28.0x P/E with a 2.5% terminal growth rate discounted at 10.555% Ke, yielding the house fair value midpoint of $342.77.26
Even in an operational beat driven by instrument placements and consumable strength, market pricing already discounts aggressive acceleration. Intrinsic valuation remains deeply disconnected from fundamental fair value.
In-line financial performance confirms the steady compounder thesis but validates that high single-digit revenue growth cannot support an elevated forward valuation multiple.
An operational or volume miss exposes the multiple to sharp contraction toward peer median levels as growth premiums evaporate under macro clinical visit pressure.
IDEXX exhibits high earnings quality supported by pure cash conversion and minimal revenue recognition ambiguity. In Q2 2026, GAAP net income of $338.41 million converted into $347.16 million of operating cash flow and $322.52 million of free cash flow. For full-year FY2026, free cash flow conversion is guided at 90% to 100% of net income. Working capital dynamics remain exceptionally stable, with days sales outstanding holding at 46.2 days and inventory turns steady at 1.4x. Reported EPS includes a modest $0.24 full-year benefit from share-based compensation tax adjustments, but core operating profitability reflects uncompromised cash generation.
Consensus earnings estimates adjusted slightly higher following Q2 2026 results, with FY2026 EPS moving from $14.66 to $14.84 per share to reflect management's updated guidance range of $14.69-$14.94. FY2026 revenue consensus adjusted marginally to $4,724.59 million. Over the quarterly revision window, material revisions remained absent, characterizing consensus estimate momentum as stable and flat.15
Recurring consumable and reference laboratory testing accounts for the vast majority of segment revenues, representing the core annuity cash generator.
Persistent veterinary clinic foot-traffic headwinds restrict consumable cartridge pull-through and signal discretionary pet care fatigue.
Cash generation is exceptionally clean and volume-driven. In FY2025, operating cash flow reached $1,181.81 million, delivering $1,057.13 million in free cash flow after $124.68 million in capital expenditures. In Q2 2026, free cash flow was $322.52 million, and full-year FY2026 free cash flow conversion is guided at 90% to 100% of net income. Working capital requirements remain low, with days sales outstanding stable at 46.2 days.56
IDEXX maintains an asset-light capital structure with $196.93 million in cash and $1,096.08 million in total debt, yielding modest leverage. However, management allocates almost all discretionary to share buybacks ($697.84 million in 6M 2026 at an average cost of $592.41 per share). Repurchasing stock at market prices between $565 and $592 per share—well above the house midpoint of $342.77 —represents value-dilutive capital deployment.
IDEXX delivers world-class return on invested capital driven by operating margins expanding from 31.60% in FY2025 to 32.40% in FY2026 and 34.00% by FY2030. High asset turnover and proprietary consumable pricing power sustain high economic profit.
ROIC exceeds 25%, maintaining a wide positive spread of more than 15 percentage points above the firm's 10.41% WACC, confirming exceptional franchise quality.
CAG Diagnostics recurring revenue reached $974.71 million in Q2 2026, growing 10.3% organically with VetLab consumables up 13.6% organically.
| 营业收入 | US$1,216,585,000 |
|---|---|
| 营业成本 | US$437,498,000 |
| 毛利 | US$779,087,000 |
| 营业费用 | US$353,521,000 |
| 营业利润 | US$425,566,000 |
| 营业外项目及税项 | -US$87,154,000 |
| 净利润 | US$338,412,000 |
| 总资产 | US$3,350,759,000 |
|---|---|
| 现金 | US$180,070,000 |
| 流动资产 | US$1,413,827,000 |
| 总负债 | US$1,745,376,000 |
| 流动负债 | US$1,148,814,000 |
| 股东权益 | US$1,605,383,000 |
| 净利润 | US$1,059,464,000 |
|---|---|
| 经营现金流入 | US$1,264,660,000 |
| 折旧与摊销 | US$145,183,000 |
| 股份支付 | US$60,013,000 |
| 经营现金流 | US$1,181,805,000 |
| 经营现金流出 | US$82,855,000 |
| 可用现金 | US$1,481,273,000 |
| 期初现金 | US$288,266,000 |
| 汇率影响 | US$11,202,000 |
| 投资现金流出 | US$136,239,000 |
| 资本支出 | US$124,676,000 |
| 其他投资活动 | US$11,563,000 |
| 融资现金流出 | US$1,164,964,000 |
| 期末现金 | US$180,070,000 |
| 投资现金流 | -US$136,239,000 |
| 融资现金流 | -US$1,164,964,000 |
来源: SEC EDGAR · 申报日期 2026-02-20 · SEC EDGAR
| 按经营分部划分的收入 | 营业收入 | 占比 | 同比 |
|---|---|---|---|
| Companion Animal Group | US$39.5亿 | 91.9% | 10.6% |
| Water | US$2亿 | 4.7% | 8.7% |
| Livestock And Poultry Diagnostics | US$1.3亿 | 3.1% | 8% |
2026-10-22分析所采用的时点财务数据。
| 期间 | 营业收入 | EBITDA | 净利润 | 经营现金流 | 自由现金流 | 资本支出 | 折旧与摊销 | 股份支付 | 股份回购 | 已付股息 | 净债务发行 | 投资现金流 | 融资现金流 | 期初现金 | 期末现金 | 现金与投资 | 总债务 | 营业利润率 | ROIC | WACC | ROIC−WACC利差 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | US$17.8亿 | US$4.3亿 | US$2.2亿 | US$3.4亿 | US$2.7亿 | US$6478.7万 | US$7821.8万 | US$1989.1万 | US$3亿 | US$0 | — | -US$9078.6万 | -US$2.2亿 | — | US$1.5亿 | US$3.9亿 | US$5.9亿 | 19.7% | — | 5.6% | — |
| 2017-12-31 | US$19.7亿 | US$5亿 | US$2.6亿 | US$3.7亿 | US$3亿 | US$7438.4万 | US$8314万 | US$2351.7万 | US$2.8亿 | US$0 | — | -US$1.4亿 | -US$2.1亿 | US$1.5亿 | US$1.9亿 | US$4.7亿 | US$6.1亿 | 21.0% | — | 5.1% | — |
| 2018-12-31 | US$22.1亿 | US$5.7亿 | US$3.8亿 | US$4亿 | US$2.8亿 | US$1.2亿 | US$8317.8万 | US$2515.7万 | US$3.7亿 | — | — | US$1.4亿 | -US$6亿 | US$1.9亿 | US$1.2亿 | US$1.2亿 | US$6亿 | 22.2% | — | 6.2% | — |
| 2019-12-31 | US$24.1亿 | US$6.4亿 | US$4.3亿 | US$4.6亿 | US$3亿 | US$1.5亿 | US$8801.1万 | US$3927.8万 | US$3亿 | US$3610.6万 | — | -US$2.1亿 | -US$2.9亿 | US$1.2亿 | US$9032.6万 | US$9032.6万 | US$7亿 | 23.0% | — | 5.5% | — |
| 2020-12-31 | US$27.1亿 | US$7.9亿 | US$5.8亿 | US$6.5亿 | US$5.4亿 | US$1.1亿 | US$9599.8万 | US$3095.1万 | US$1.8亿 | US$5132.8万 | — | -US$1.1亿 | -US$2.5亿 | US$9032.6万 | US$3.8亿 | US$3.8亿 | US$9.1亿 | 25.7% | — | 4.6% | — |
| 2021-12-31 | US$32.2亿 | US$10.4亿 | US$7.4亿 | US$7.6亿 | US$6.4亿 | US$1.2亿 | US$1亿 | US$3775.5万 | US$7.5亿 | US$4656.5万 | — | -US$2.9亿 | -US$7亿 | US$3.8亿 | US$1.4亿 | US$1.4亿 | US$8.5亿 | 29.0% | — | 5.3% | — |
| 2022-12-31 | US$33.7亿 | US$10.1亿 | US$6.8亿 | US$5.4亿 | US$3.9亿 | US$1.5亿 | US$1.1亿 | US$4977万 | US$8.2亿 | — | US$4.3亿 | -US$2亿 | -US$3.7亿 | US$1.4亿 | US$1.1亿 | US$1.1亿 | US$7.7亿 | 26.7% | — | 8.2% | — |
| 2023-12-31 | US$36.6亿 | US$11亿 | US$8.5亿 | US$9.1亿 | US$7.7亿 | US$1.3亿 | US$1.1亿 | US$5973.9万 | US$7192万 | — | -US$4亿 | -US$1.3亿 | -US$4.4亿 | US$1.1亿 | US$4.5亿 | US$4.5亿 | US$7亿 | 30.0% | — | 8.2% | — |
| 2024-12-31 | US$39亿 | US$12.8亿 | US$8.9亿 | US$9.3亿 | US$8.1亿 | US$1.2亿 | US$1.3亿 | US$6029.5万 | US$8.4亿 | — | -US$7500万 | -US$2.1亿 | -US$8.8亿 | US$4.5亿 | US$2.9亿 | US$2.9亿 | US$6.2亿 | 29.0% | — | 8.8% | — |
| 2025-12-31 | US$43亿 | US$15.1亿 | US$10.6亿 | US$11.8亿 | US$10.6亿 | US$1.2亿 | US$1.5亿 | US$6001.3万 | US$12.2亿 | — | -US$3038.5万 | -US$1.4亿 | -US$11.6亿 | US$2.9亿 | US$1.8亿 | US$1.8亿 | US$4.5亿 | 31.6% | — | 9.1% | — |
IDEXX Laboratories Inc. (IDXX) trades at 31.5x forward earnings against a peer median of 22.7x. Its EV/EBITDA of 27.4x compares with a peer median of 22.4x. The comparison uses 4 peers: IQVIA Holdings Inc., Illumina, Inc., Agilent Technologies Inc. and Labcorp Holdings Inc., as of 2026-10-22.
IDEXX is expanding capital expenditures to approximately $180 million in FY2026, up from $124.68 million in FY2025, scaling manufacturing for inVue Dx and expanding international distribution capacity. Industry capex-to-revenue stands at 4.5% and capex-to-depreciation at 0.8x.56
Sustained post-pandemic pet humanization, an aging demographic of companion animals driving recurring chronic disease diagnostics, rapid international veterinary practice modernization, and standard-of-care adoption of multi-cancer liquid biopsy screening.
Persistent contraction in veterinary clinical foot traffic (-1.3% in Q2 2026), discretionary pet care spending trade-down, veterinary technician and clinician staffing shortages, and pushback against veterinary fee inflation.
IDEXX occupies an undisputed leadership position in companion animal diagnostics, with over 91% of revenue generated in the CAG segment ($3,953.29 million in FY2025). Its proprietary razor-blade model insulates the business from standard capital equipment cycles, although demand-led clinical visit headwinds limit immediate volume acceleration.7
The committee rating is Sell based on an implied return of -39.4% to Fair value of $342.77 against $565.45. Maintaining a zero portfolio allocation is required to eliminate valuation downside risk.
Risk management under a Sell rating requires decisive divestment discipline. With the equity claim trading at a 64.96% premium to fundamental intrinsic value,, holding shares exposes capital to severe drawdown risk upon any estimate deceleration or multiple contraction. Strict divestment protects capital far more effectively than waiting for cyclical stabilization.
Trading at $565.45 against a fair value midpoint of $342.77, IDEXX offers an implied return of -39.38%. Current prices discount 19.4% annual cash flow growth—an unrealistic hurdle for an established compounder growing top line at 7.0%-9.8%.4
IDEXX's wide competitive moat, 9,000+ inVue Dx placements, and high-90s% customer retention confirm best-in-class business quality. However, exceptional business quality does not justify paying 31.45x forward P/E during a clinical visit downturn.45
U.S. clinical visits declined 1.3% in Q2 2026 with wellness visits down over 3%. Multiple compression toward peer levels (such as Agilent at 26.07x) creates an unfavorable risk-reward profile.35
IDEXX Laboratories is rated Sell. While the company operates a wide-moat, highly recurring razor-blade business model with exceptional 32.4% operating margins, the current share price of $565.45 sits 64.96% above the house fair value midpoint of $342.77, representing an implied return of -39.38%.4
The market's aggressive 31.45x forward P/E multiple leaves zero margin of safety against macroeconomic visit contraction (-1.3% in Q2 2026) or capital reinvestment step-ups ($180M CapEx in FY2026). Investors should reallocate capital away from IDXX into assets offering positive risk-adjusted spreads.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Consolidated operating margin stood at 31.60% in FY2025 and is guided to 32.3%-32.5% in FY2026. Persistent veterinary wage inflation, aggressive reference laboratory pricing discounting, and elevated commercial R&D spending compress margins back to 31.0%, triggering a 15.8% fair value reduction.56
Triggers severe equity de-rating toward specialized diagnostics peer averages such as Agilent at 26.07x, destroying shareholder value.
当前：31.45x forward earnings as of 2026-10-22
触发警报：De-rating below 23.0x forward earnings
Signals cost inflation pass-through failure, aggressive reference laboratory discounting, or R&D inefficiencies, reducing operating profit flow-through.
当前：31.60% in FY2025; guided to 32.3%-32.5% in FY2026
触发警报：Consolidated operating margin falling below 31.0%
Breaches the fundamental compounder thesis, indicating diagnostic utilization saturation and an inability to offset volume softness with net pricing.
当前：10.3% organic growth in Q2 2026; guided to 9.5%-10.7% for FY2026
触发警报：Deceleration below 7.0% organic growth
Signals slowing clinic adoption of slide-free cellular technology, curtailing high-margin recurring test cartridge revenue growth.
当前：1,600+ placements in Q2 2026; pacing toward ~5,500 full-year placements
触发警报：Quarterly placements falling below 1,200 units
| medium |
| Long-term (3-5 years) |
| Aggressive R&D reinvestment into proprietary menu expansions, such as inVue Dx slide-free cytology and Cancer Dx screening panels, which competitors cannot match.5 |
| Veterinary Practice Footfall Weakness and Discretionary Testing Deferral | high | Near-term (12-18 months) | Accelerating international expansion (growing 13.4% in Q2 2026) and driving higher diagnostic test intensity per sick-patient visit to offset wellness visit headwinds.5 |
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and terminal value at WACC, then adjust for signed net debt per current share.
Discounted forecast-period cash flows (US$61.72) plus discounted terminal value (US$171) minus signed per current share (US$1.80) equals the US$231 lens value shown above. Negative net debt is , so subtracting it raises value.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Solve for the growth rate that makes the model value equal the report-date share price.
Rapid international market penetration and widespread clinical adoption of inVue Dx and Cancer Dx screening panels accelerate organic revenue growth above 10.0%. Consumable volume expansion drives operating margins to 35.0% by FY2028, while premium multiple durability supports a 34.0x terminal P/E multiple, pushing equity fair value toward the upper band of $440.34.
Rapid adoption of slide-free cellular analyzers drives multi-year high-margin cytology cartridge revenue.
Validates whether gross margin leverage can overcome commercial R&D spending and veterinary labor inflation.
International clinics represent the primary geographic growth runway as North American clinic penetration matures.
| $5.56B |
| $5.98B |
| $6.40B |
| Revenue growth | 9.8% | 8.8% | 8.2% | 7.5% | 7.0% |
| Operating margin | 32.4% | 33.0% | 33.4% | 33.7% | 34.0% |
| Operating income | $1.53B | $1.70B | $1.86B | $2.02B | $2.18B |
| Tax rate | 20.1% | 20.5% | 21.0% | 21.0% | 21.0% |
| NOPAT | $1.22B | $1.35B | $1.47B | $1.59B | $1.72B |
| Reinvestment | $146.80M | $148.37M | $146.78M | $159.21M | $154.68M |
| Reinvestment rate (of NOPAT) | 12.0% | 11.0% | 10.0% | 10.0% | 9.0% |
| Free cash flow to firm | $1.08B | $1.20B | $1.32B | $1.43B | $1.56B |
| Companion Animal Group revenue | $4.34B | $4.72B | $5.11B | $5.49B | $5.88B |
| Water revenue | $220.68M | $240.10M | $259.79M | $279.27M | $298.82M |
| Livestock and Poultry Diagnostics revenue | $144.60M | $157.32M | $170.22M | $182.99M | $195.80M |
| Terminal growth | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% |
Gross margin rose 140 basis points to 64.0% in Q2 2026, supporting full-year FY2026 operating margin guidance of 32.3%-32.5% compared to 31.60% in FY2025.
Incremental consumable volume yields high gross profit flow-through, enabling IDEXX to fund innovation while expanding operating margins.
CapEx is stepping up to ~$180 million in FY2026 from $124.68 million in FY2025, while open-market share buybacks absorbed $692.88 million in 6M 2026 at $592.41 per share.
Executing large-scale buybacks at a 64.96% premium over intrinsic fair value ($342.77) destroys economic value for long-term shareholders.
| 利润率 |
|---|
| IDXX | IDEXX Laboratories Inc. | $44.6B | 31.5x | 9.8x | 27.4x | 74.2% | — |
| IQV | IQVIA Holdings Inc. | $45.9B | 19.4x | 2.7x | 19.6x | 22.8% | 13.0% |
| ILMN | Illumina, Inc. | $40.9B | 44.2x | 9.1x | 38.2x | 32.3% | 21.1% |
| A | Agilent Technologies Inc. | $49.6B | 26.1x | 6.7x | 25.2x | 21.0% | 25.6% |
| LH | Labcorp Holdings Inc. | $26.4B | 16.5x | 1.8x | 14.2x | 11.7% | 12.2% |
| Below 32.0% in any reported quarter |
| Verify margin erosion from labor inflation or reference laboratory price competition. |
| inVue Dx Analyzer Placements | Fewer than 1,200 placements per quarter | Downgrade long-term consumable cartridge adoption and revenue expectations. |
